Streptococcal C5a peptidase vaccine

• US 5,846,547 A
• Filed: 01/22/1996
• Issued: 12/08/1998
• Est. Priority Date: 01/22/1996
• Status: Expired due to Term

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Cleary, Paul Patrick
• Primary Examiner(s): LORING, SUSAN
• Application Number:
  US08/589,756
• Time in Patent Office: 1,051 Days
• Field of Search: 424/244.1, 424/234.1
• US Class Current: 424/244.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/092 Streptococcus
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: C12N 9/52 derived from bacteria or Archaea
• CPC Class Codes: C12Y 304/2111 C5a peptidase (3.4.21.110)

Abstract

Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine.

Claims

1. A vaccine comrising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against β

-hemolytic Streptococcus colonization or infection in a susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle.

2. The vaccine of claim 1 which further comprises an effective amount of an immunological adjuvant.

3. The vaccine of claim 1 wherein said mammal is selected from the group consisting of human, dog, bovine, porcine and horse.

4. The vaccine of claim 3 wherein said mammal is human.

5. The vaccine of claim 1 wherein said β

-hemolytic Streptococcus is selected from the group consisting of group A Streptococcus, group B Streptococcus, group C Streptococcus and group G Streptococcus.

6. A method according to claim 5, wherein said β

-hemolytic Streptococcus is Group A Streptococcus.

7. The vaccine of claim 1, which comprises a recombinant streptococcal C5a peptidase, conjugated or linked to a protein selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin.

8. The vaccine of claim 1, which comprises said streptococcal C5a peptidase, conjugated or linked to a polysaccharide selected from the group consisting of group A Streptococci polysaccharide, capsular polysaccharides from group B Streptococci and capsular polysaccharides of Streptococci pnuemoniae.

9. A method of protecting a susceptible mammal against β

-hemolytic Streptoccocus colonization or infection comprising administering to said mammal an effective amount of a vaccine comprising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against Streptococcus colonization or infection in said susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle.

10. The method of claim 9 wherein said vaccine further comprises an effective amount of an immunological adjuvant.

11. The method of claim 9 wherein said vaccine is administered by subcutaneous or intramuscular injection.

12. The method of claim 9 wherein said vaccine is administered by oral ingestion.

13. The method of claim 9 wherein said vaccine is administered intranasally.

14. A method according to claim 9, wherein said p-hemolytic Streptococcus is selected from the group consisting of group A Streptococcus, group B Streptococcus, group C Streptococcus and group G Streptococcus.

15. A method according to claim 14, wherein said β

-hemolytic Streptococcus is group A Streptococcus.

16. The method according to claim 9 wherein said mammal is selected from the group consisting of a human, dog, bovine, porcine, and horse.

17. The method according to claim 16 wherein said mammal is human.

18. The method of claim 9, wherein said vaccine comprises a recombinant streptococcal C5a peptidase, conjugated or linked to a protein selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin.

19. The method of claim 9, wherein said vaccine comprises a recombinant C5a peptidase, conjugated or linked to a polysaccharide selected from the group consisting of group A Streptococci polysaccharide, capsular polysaccharides from group B Streptococci and capsular polysaccharides of Streptococci pnuemoniae.